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Abstract
Purpose In planar
123I-metaiodobenzylguanidine (
123I-
MIBG) myocardial imaging mediastinum (M) activity is
often used as a background correction in calculating
“washout” (WO). However, the most likely sources for
counts that might produce errors in estimating myocardial
(Myo) activity are lung (Lu) and liver (Li), which typically
have higher counts/pixel (cpp) than M. The present study
investigated the relationship between changes in Lu, Li
and Myo activity between early and late planar
123I-MIBG
images, with comparison to M as the best estimator of
non-specific background activity.
Methods Studies on 98 subjects with both early (e) and late (l)
planar
123I-MIBG images were analysed. There were 68
subjects with chronic heart failure (CHF), 14 with hypertension
(HTN) but no known heart disease and 16 controls (C). For
each image, regions of interest (ROIs) were drawn: an irregular
whole Myo, Lu, upper M and Li. For each ROI, WO was
calculated as [(cpp(e)-cpp(l:decay corrected))/cpp(e)]×100%.
Results Multivariable forward stepwise regression analysis
showed that overall a significant proportion of the variation in
Myo WO could be explained by a model containing M WO
and Lu WO (37%, p<0.001). Only in controls was M WO
the sole variable explaining a significant proportion of the
variation in Myo WO (27%, p=0.023).
Conclusion Although increased Myo WO in CHF subjects
reflects disease severity, part of the count differences
measured on planar
123I-MIBG myocardial images likely
reflects changes in the adjacent and surrounding Lu tissue.
The results for the controls suggest that this is the only
group where a mediastinum correction alone may be
appropriate for cardiac WO calculations.
Keywords Heartfailure.Quantification.MIBG
Introduction
Radiolabelled metaiodobenzylguanidine (
123I-MIBG), an
analogue of the false neurotransmitter guanethidine, local-
izes in adrenergic nerve terminals primarily via the
norepinephrine (NE) transporter (uptake-1) [1, 2]. In the
past two decades, a large number of investigators have
demonstrated decreased myocardial
123I-MIBG uptake in
patients with chronic heart failure (CHF) and have shown
that those with the lowest uptake tend to have the poorest
prognosis [3–13]. There have also been findings suggesting
that abnormalities of myocardial
123I-MIBG uptake may be
predictive of increased risk for ventricular arrhythmia and
sudden cardiac death [14–16].
Cardiac uptake of
123I-MIBG is rapid, reaching a relative
plateau within a few minutes post-injection [2, 17, 18].
Over the next few hours post-injection, myocardial
123I-
MIBG activity typically decreases; the magnitude of this
cardiac washout is usually interpreted as a reflection of
neuronal integrity (ability to retain NE in presynaptic
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Princeton, NJ, USAgranules). In normal myocardium, change in myocardial
123I-
MIBG activity during the first 2–4 h post-injection is
relatively small, with estimated means of 6–8% between 15
and 85 min by single photon emission computed tomogra-
phy (SPECT) [19]a n d7 –10% between 15 min and 2.5–3
h from planar images [20, 21]. In patients with heart disease,
particularly those with CHF, myocardial
123I-MIBG activity
decreases more rapidly. This increased myocardial washout
has been associated with adverse prognosis [5, 9, 12].
In most early reports which examined the significance of
increased
123I-MIBG myocardial washout, this parameter
was calculated as the simple percentage change in region of
interest (ROI) counts or counts/pixel (cpp) between early
(e: typically 15–30 min) and late (l: 3–4h )p l a n a ro r
SPECTimages[19, 22, 23]. Although background correction
is often utilized in quantitative nuclear imaging (e.g. cardiac
gated blood pool and renal scintigraphy), such correction is
more challenging with
123I-MIBG studies because of the
frequently high lung activity in patients with heart failure
[19]. As a consequence, investigators have tended to use the
mediastinum as a more consistent background correction for
calculation of the parameter of myocardial washout. Typical
123I-MIBG myocardial washout data published in the past
20 years are based upon mediastinum-corrected calculations
[13, 24–26], even though the most likely sources for non-
cardiac counts in the myocardial ROI are the lungs and liver,
which typically have higher cpp than mediastinum. In
addition to these confounding factors, the precise relation-
ship between calculated values of myocardial
123I-MIBG
washout and the presynaptic kinetics of NE are not
completely understood [27].
The objective of the present study was to investigate the
degree to which changes in lung and liver activity
contribute to changes in myocardial activity between early
and late planar
123I-MIBG images. Comparisons were also
made to mediastinum as the best estimator of non-specific
background activity.
Methods
Study design
Data from myocardial
123I-MIBG scintigrams collected as
part of a previously described trial were utilized in the
present analyses [28]. The primary focus of the previous
publication was the prognostic significance of the late heart
to mediastinal ratio (H/M ratio) in 290 subjects with CHF.
In only 68 patients with CHF from the former study
population were both early and late
123I-MIBG scintigrams
available. For the present analyses these 68 CHF subjects
were examined. Data from 14 subjects with hypertension
(HTN) but no known heart disease and 16 normal control
subjects, collected as part of the trial but not previously
described, were also analysed. In all 98 subjects both early
and late
123I-MIBG scintigrams were available.
Image acquisition and analysis
All images had been acquired in a 128×128 matrix. Early
(e) images were acquired 15–30 min post-injection, while
the late (l) images were acquired a mean of 3.6 h later
(range: 1.2–5.1 h).
An experienced nuclear medicine technologist processed
all images for this study. For each image (e and l), seven
regions of interest (ROIs) were drawn (Fig. 1). The
myocardial ROI was drawn manually to include all visible
ventricular activity. All other ROIs were square with
dimensions of 7×7 pixels. The mediastinal ROI was drawn
in the upper mediastinum, using the apices of the lungs as
anatomical landmarks. One ROI was drawn in the midline
of each lung, with the left lung ROI positioned more
superiorly to minimize proximity to the heart. Three
adjacent liver ROIs were drawn at the same horizontal
level, one in the right lobe, one in the left lobe and the third
halfway between the other two. The cpp in each ROI was
used in all calculations.
Washout in each ROI was calculated as: [(cpp(e)-cpp(l:
decay corrected))/cpp(e)]×100%. As there were no differ-
ences in the results for the two lung or the three liver ROIs,
the respective data were combined to produce aggregate
lung (Lu) and liver (Li) washout data for further analysis.
Statistical analysis
Data are presented as mean±standard deviation, unless
indicated otherwise. Differences between groups for con-
Fig. 1 Example of processing procedure for late planar
123I-MIBG
images. The positioning of the mediastinal ROI was standardized in
relation to the lung apex, the lower boundary of the upper
mediastinum and the midline between the lungs
Eur J Nucl Med Mol Imaging (2009) 36:1322–1328 1323tinuous data were compared using analysis of variance
(ANOVA) with a post hoc Bonferroni. Categorical data
were compared using Fisher’s exact test. A forward
stepwise multivariable regression analysis was performed
to determine independent predictors of
123I-MIBG myocar-
dial washout. Changes in mediastinal, lung and liver
activity between early and late
123I-MIBG images were
used as explanatory variables. The overall goodness-of-fit
for each model was expressed as the adjusted R
2. The F test
was used to assess whether a model explained a significant
proportion of the variability. A p value<0.05 was consid-
ered to indicate a statistically significant difference. All
statistical analyses were performed with SPSS (SPSS for
Windows, version 16.0.2, SPSS Inc, Chicago, IL, USA).
Results
Table 1 shows the baseline characteristics of all subjects and
for thethreedifferentsubjectgroups.CHFsubjectsweremore
often male compared to hypertension subjects but not
compared to controls. Control and hypertension subjects were
younger than those with CHF. Among CHF subjects, the
aetiology of heart failure was ischaemic in 27 (40%) and non-
ischaemic in 41 (60%). The mean left ventricular ejection
fraction for the CHF subjects was 26.5% (range: 7–47%).
Myocardial washout was significantly higher in CHF
subjects than in subjects with HTN or in controls (Table 2,
p<0.001 and p=0.005, respectively). There were no differ-
ences in washout for lung and mediastinum across the three
populations. Liver washout was significantly higher in
controls than in CHF subjects (p=0.007).
Table 3 shows the results of the stepwise multivariable
regression analysis for all subjects. Mediastinal and lung
washout were independent predictors of myocardial wash-
out. This model predicted approximately 37% of the
variation in myocardial washout (p<0.001).
In subjects with CHF, stepwise multivariable regres-
sion analysis showed mediastinal and lung washout to
be independent predictors of myocardial washout
(Table 4). This model predicted approximately 60% of
myocardial washout (p<0.001). In subjects with HTN,
stepwise multivariable regression analysis showed that liver
and lung washout were independent predictors of myo-
cardial washout (Table 5). This model predicted approx-
imately 76% of myocardial washout (p<0.001). In
controls, mediastinal washout was the sole independent
predictor of myocardial washout (Table 6). Although
mediastinal washout explained a statistically significant
proportion of variability (p=0.023), only 27% of the
variation in myocardial washout was predicted by mediastinal
washout.
Table 1 Patient parameters for all subjects and subdivided by patient subgroup
Patient characteristics All (n=98) Patient subgroup
CHF HTN Controls
(n=68) (n=14) (n=16)
Male/female
a 74/24 57/11 7/7 10/6
Age (years)
b 52.8±13.0 (range 22–83) 56.6±11.1 42.9±13.9 44.9±12.3
Data are presented as mean ± standard deviation.
CHF subjects with chronic heart failure, HTN subjects with hypertension
aGender: p=0.02 for CHF vs HTN; p=0.205 for CHF vs controls; p=0.826 for HTN vs controls
bAge: p<0.001 for CHF vs HTN; p=0.002 for CHF vs controls; p=0.735 for HTN vs controls
Table 2 Myocardial, mediastinal, lung and liver
123I-MIBG washout
n Myocardial washout
a Mediastinal washout Lung washout Liver washout
b
Overall 98 22.50 (9.35) 17.10 (9.31) 29.20 (10.78) 9.09 (21.49)
CHF 68 25.20 (8.24) 16.50 (10.00) 28.74 (11.65) 5.56 (22.30)
HTN 14 14.92 (7.08) 18.27 (8.25) 27.44 (6.88) 9.73 (13.58)
Controls 16 17.65 (10.34) 18.64 (7.10) 32.73 (9.33) 23.56 (18.02)
aMyocardial washout: p=0.005 for CHF vs controls and p<0.001 for CHF vs HTN
bLiver washout: p=0.007 for CHF vs controls
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The most important determinants of cardiac uptake and
retention of
123I-MIBG are the functional status of the NE
transporter (NET) and the vesicular monoamine transporter
(VMAT) in presynaptic adrenergic neurons [3–11]. Impair-
ment of either or both transporters can result in reduced
neuronal uptake and increased rate of loss of NE and its
analogue
123I-MIBG.
Given the physical and physiological characteristics of
MIBG and the isotope
123I, it is not surprising that there can
be considerable variation in myocardial washout assess-
ments based on planar
123I-MIBG images. The key
assumptions that underlie the simple methods used to
calculate myocardial washout, namely that the counts in
the myocardial ROI reflect only specific and non-specific
neuronal uptake of
123I-MIBG and that the mediastinum
ROI represents the non-specific/background cpp for the
myocardium, have never been carefully validated. The
findings of the present study indicate that the latter
assumption is at best only partially correct in that a
proportion of the variation in the myocardial
123I-MIBG
washout for CHF and HTN patients can also be explained
by washout of
123I-MIBG in surrounding lung and liver
tissue. Only in controls does the use of a mediastinum
correction alone appear appropriate, and even in this group,
the proportion of the variation of calculated myocardial
washout associated with mediastinum washout is relatively
small.
Change in organ uptake over time has long been utilized
as an adjunctive physiological assessment in nuclear
imaging. For example, change in
201Tl uptake between
early and late images has been used as both a primary
indicator of stress-induced ischaemic (“redistribution”) and
a secondary indicator of coronary artery disease (CAD)
severity (“washout”)[ 29]. The frequent association of
increased cardiac washout of
123I-MIBG and heart failure
and other heart diseases was noted within a few years of the
initial reports of
123I-MIBG imaging results [19, 22, 23].
This phenomenon has now been extensively studied for
more than 20 years. While the physiological processes
associated with neuronal uptake and loss of
123I-MIBG are
clearly important, the present results suggest that method-
ological issues must also be considered, particularly for
analysis of planar images. As a quantitative parameter,
“washout” should reflect only changes in the organ under
investigation, a condition that is clearly not met for the
myocardial ROI in planar
123I-MIBG imaging. In addition,
successful background correction in nuclear imaging
usually requires a high count target organ surrounded by
tissues with relatively homogeneous lower activity. How-
ever, for
123I-MIBG myocardial imaging in CHF, lung cpp
is often greater than myocardial cpp, and the contribution of
liver counts to the myocardial cpp is greatly dependent on
the location and size of the left lobe. In most instances, use
of the mediastinum cpp as background correction is
unlikely to produce a reliable estimate of the net activity
in the myocardium.
Despite its methodological deficiencies, the strong
prognostic value of mediastinal background-corrected myo-
cardial
123I-MIBG washout has been repeatedly demon-
strated [24, 25]. While such calculated washout rates are
probably not a true reflection of neuronal NET and VMAT
status [30], they are still clearly related to the severity of
neuronal dysfunction associated with CHF. The contribu-
tion of changes in lung activity to the calculated washout in
CHF patients may enhance the prognostic significance of
this parameter, possibly incorporating elements of abnormal
Variables Coefficient b Standard error bp value
Constant 7.546 2.171
Mediastinal washout 0.255 0.111 0.023
Lung washout 0.531 0.087 <0.001
Goodness-of-fit of the model Adjusted R
2 p value
0.372 <0.001
Table 3 Multivariable analysis
of mediastinal, lung and liver
123I-MIBG washout as predic-
tors of
123I-MIBG myocardial
washout for all subjects (n=98)
Variables Coefficient b Standard error bp value
Constant 10.416 1.710
Mediastinal washout 0.263 0.095 0.007
Lung washout 0.364 0.081 <0.001
Goodness-of-fit of the model Adjusted R
2 p value
0.595 <0.001
Table 4 Multivariable analysis
of mediastinal, lung and liver
123I-MIBG washout as predic-
tors of
123I-MIBG myocardial
washout for chronic heart failure
subjects (n=68)
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as a consequence of myocardial dysfunction. The findings
of the present study suggest that especially in CHF patients
a better understanding of the significance of changes in
lung activity might improve the validity and value of the
calculation of myocardial washout.
In CHF patients, sympathetic activity is initially
increased as a compensatory mechanism. However, chron-
ically elevated stimulation of the adrenergic system is
associated with sustaining the process of remodelling.
Abnormalities in calculated myocardial
123I-MIBG washout
have been demonstrated in patients with most common
cardiac pathological conditions such as CAD, CHF, and
non-ischaemic cardiomyopathy [5, 9, 12, 14, 31, 32]. In
fact, most studies have shown that both late H/M and
123I-
MIBG myocardial washout are abnormal in these cardiac
disease populations. Multivariable models have variously
shown late H/M and
123I-MIBG myocardial washout as the
most powerful predictors of outcome [7, 9, 12, 16]. The
problem with most of these analyses is that they treated
washout and H/M as independent variables, when in fact
they are related, employing the same ROI cpp data in the
calculations. As shown in the present study, the degree of
relationship between these variables may depend on the
population being studied.
The differences between the three groups included in this
study provide insight into the physiology of
123I-MIBG and
the physical attributes of planar
123I-MIBG imaging. A
consistent feature of
123I-MIBG imaging in all individuals
is high liver uptake, but only in HTN subjects did this
organ contribute to variability in calculated myocardial
washout. Whether this is a reflection of a change in
sympathetic tone in the liver as a result of chronic
hypertension is uncertain but may warrant further investi-
gation. The finding that lung activity significantly contrib-
utes to myocardial activity in CHF subjects is consistent
with the frequent visualization of prolonged lung uptake on
delayed
123I-MIBG images. This suggests that some
allowance for this phenomenon is needed for an accurate
assessment of change in specific myocardial uptake over
time in these subjects.
There was significantly higher myocardial washout in
CHF than HTN or control subjects, which is in keeping
with previous observations. In addition, washout from
lungs was of a magnitude similar to that from myocardium.
These findings suggest that there is a component of the
change in myocardial cpp common to that of the lungs [e.g.
clearance of blood pool activity, release of non-specific
tracer accumulation (uptake-2)]. There is little doubt that
changes in counts detected in the myocardium reflect a
component of counts that originated from
123I emissions in
the lungs. This is also consistent with the known effect of
septal penetration of high-energy
123I photons on quantita-
tive reliability of measured image counts [33, 34].
The primary limitation of the present study is the small
number of subjects included, particularly in the hyperten-
sion and control subgroups. In addition, as the largest
influence on the
123I-MIBG myocardial washout is myo-
cardial disease severity, the retrospective nature of this
study made it impossible to control for the effects of subject
selection and image acquisition variables that might have
had undetected impact on the calculated
123I-MIBG
myocardial washout.
In conclusion, myocardial washout of
123I-MIBG in
CHF subjects is likely to reflect in part changes in the
adjacent and surrounding tissue. The results for the controls
suggest that this is the only group where a mediastinum
correction alone may be appropriate for myocardial
washout calculations. Therefore, there remains the need to
better characterize the significance of myocardial washout
Variables Coefficient b Standard error bp value
Constant −3.743 3.922
Liver washout 0.296 0.073 0.002
Lung washout 0.575 0.143 0.002
Goodness-of-fit of the model Adjusted R
2 p value
0.764 <0.001
Table 5 Multivariable analysis
of mediastinal, lung and liver
123I-MIBG washout as predic-
tors of
123I-MIBG myocardial
washout in subjects with hyper-
tension (n=14)
Variables Coefficient b Standard error bp value
Constant 2.334 6.380
Mediastinal washout 0.822 0.321 0.023
Goodness-of-fit of the model Adjusted R
2 p value
0.270 0.023
Table 6 Multivariable analysis
of mediastinal, lung and liver
123I-MIBG washout as predic-
tors of
123I-MIBG myocardial
washout for controls (n=16)
1326 Eur J Nucl Med Mol Imaging (2009) 36:1322–1328determined from early and late planar
123I-MIBG images.
While an absolute determination of myocardial washout of
123I-MIBG would undoubtedly be a reflection of the
capacity of sympathetic neurons to retain the neurotrans-
mitter NE, the accuracy of the calculation method in
common use for quantifying this phenomenon is uncertain.
Particularly in CHF patients, a means to incorporate
changes in lung activity in the calculation of absolute
myocardial washout would appear to warrant further
investigation.
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